SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : SNRS- Sunrise Technologies
SNRS 0.0000010000.0%Jun 6 11:01 AM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Nanny who wrote (133)10/28/1997 9:21:00 PM
From: Mack Earnhardt  Read Replies (1) of 4140
 
Nanny,

That sounds fantastic!!!

As a PRK patient myself, I can vouch for the several days of discomfort, but I had excellent results (thanks, VISX).

For clarification, I'll mention that Sunrise's product is targeted at a different patient group than the Excimer. I was around 6 diopters "nearsighted" (technically myopia), and would never have been a candidate for the Sun 1000, which treats "farsighted" people (presbyopia), and another condition which I'm not sure of the name for but it's people who need reading glasses (hyperbyopia?)

The basic different is the center of my myopic cornea was curved out too much, and the other conditions are from not curving out enough. PRK removes tissue from the middle, while the Sand process (SNRS) uses heat to shrink tissue around the edges to give the middle some lift (kind of like a couch potato's belly when he tightens his belt <g>).

The point of all this is that it's not a case of Sunrise eating the Excimer's lunch, but actually a vast, unserved market which will pay high rewards to the first successful device manufacturer. Hopefully, that will be Sunrise instead of VISX or BEAM figuring out how to add this treatment to their existing product.

-Mack
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext